Abstract |
We evaluated whether reduced-dose chemotherapy with 2 days of idarubicin (12 mg/m(2)) and 5 days of cytarabine (100 mg/m(2)) (2 + 5) is effective for patients aged 65-74 by retrospectively comparing the results with those aged 55-64 treated with 3 + 7. In 1999-2009, we treated 20 patients aged 65-74 with 2 + 5, and 23 patients aged 55-64 with 3 + 7. The complete remission rates by the first induction were 50.0 and 69.6% for older and younger groups (P = 0.203). Two-year overall survival rates were 55.9 and 32.3% for older and younger groups; 2-year rates of relapse-free survival for all these patients were 15.7 and 36.5%. The differences in overall and relapse-free survival were statistically insignificant (P = 0.726 and 0.413, respectively). The treatment results of 2 + 5 for the older group were not significantly worse compared with those of 3 + 7 for the younger. Therefore, elderly patients who do not tolerate 3 + 7 should still benefit from 2 + 5.
|
Authors | Takashi Kobayashi, Motoshi Ichikawa, Yasuhito Nannya, Mineo Kurokawa |
Journal | Japanese journal of clinical oncology
(Jpn J Clin Oncol)
Vol. 43
Issue 10
Pg. 1047-51
(Oct 2013)
ISSN: 1465-3621 [Electronic] England |
PMID | 23956441
(Publication Type: Comparative Study, Journal Article)
|
Chemical References |
- Antibiotics, Antineoplastic
- Cytarabine
- Idarubicin
|
Topics |
- Aged
- Aged, 80 and over
- Antibiotics, Antineoplastic
(administration & dosage, adverse effects)
- Antineoplastic Combined Chemotherapy Protocols
(administration & dosage)
- Cytarabine
(administration & dosage)
- Disease-Free Survival
- Dose-Response Relationship, Drug
- Drug Administration Schedule
- Female
- Humans
- Idarubicin
(administration & dosage, adverse effects)
- Induction Chemotherapy
- Kaplan-Meier Estimate
- Leukemia, Myeloid, Acute
(drug therapy)
- Male
- Proportional Hazards Models
- Retrospective Studies
- Risk Assessment
- Risk Factors
- Treatment Outcome
|